Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.

SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma Inc. ( "Zhimeng") announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the first patient first dose at the 2nd Affiliated Hospital of Hebei Medical University. Previously (in July 2025), CB03-154 received approval from the China Center for Drug Evaluation (CDE) to conduct the ALS phase 2/3 adaptive clinical trial. The CB03-154 has also been granted orphan drug status in the United States in October 2023 for the treatment of ALS.

This phase 2/3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study with open-label extension. This study is led by Professor Fan Dongsheng from the 3rd Affiliated Hospital of Peking University as the leading investigator nationwide. This study will enroll approximately 240 patients diagnosed with ALS in about 15 centers in China. The disease duration of to be enrolled patients will be within 24 months from the first symptom onset to the screening visit. The primary efficacy endpoint of the study is the change from baseline at week 39 of the revised ALS Functional Rating Scale (ALSFRS-R) score.

Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal central nervous system disease with unknown etiology. It mainly affects the motor neurons in the cerebral cortex, brainstem, and spinal cord. The pathological features of ALS include the loss of upper and lower motor neuron cell bodies, as well as the degeneration of the corticospinal tract/corticobulbar tract and axons of lower motor neurons, and the occurrence of denervation changes in muscles. Clinically, it mainly presents as progressive skeletal muscle weakness, atrophy, fasciculation, bulbar palsy, and pyramidal tract signs. The median survival duration is generally 2 to 3 years after the onset of symptoms. The main cause of death is neuromuscular respiratory failure. The annual incidence of ALS in Europe and the United States is 2/100,000 to 3/100,000, and the prevalence rate is 3-5/100,000. The peak age of onset is 50 to 75 years. Approximately 10% of ALS patients are familial, while the remaining 90% are sporadic. Currently, there are no treatments that can stop or reverse the progression of the disease. Therefore, clinical management focuses on early diagnosis and early treatment to maximize the survival time. Currently, only three drugs have been approved worldwide for ALS, namely Riluzole, Edaravone, and Tofersen (trade name Qalsody). These approved drugs can only slightly improve the patient's function or slightly prolong the survival time. Therefore, ALS still has a huge unmet medical need.

Although the pathogenesis of ALS has not been fully deciphered, studies have found that it is closely related to changes in ion channels, synaptic transmission and connections, as well as the imbalance of excitation and inhibition of neurons. Among them, the potassium ion (K+) channel is the most widely distributed and has the largest variety, mainly participating in regulating the excitability of neurons and the frequency and amplitude of action potential generation. Currently, there are no marketed KCNQ2/3 potassium ion channel openers available for ALS patients. The only KCNQ2/3 potassium ion channel opener that was approved by the FDA and EMA, ritigabine (Potiga, Ezogabine/Retigabine), was once studied in ALS patients and showed a favorable signal. However, due to the risks of pigmentation-induced vision impairment and other risk factors, it was withdrawn from the market in 2017.

CB03-154 is a new generation selective voltage-gated potassium channel (KCNQ2/3) opener, independently developed by Zhimeng. Compared with the first-generation potassium channel opener ritigabine, CB03-154 has superior selectivity and stability. In vitro studies have confirmed that CB03-154 can significantly reduce the excessive excitation of iPSC motor neurons from ALS patients. Moreover, in the SOD-1 ALS transgenic mouse model, daily oral administration of CB03-154 (10 mg/kg) can effectively prolong the survival time, delay the onset, improve motor ability, alleviate neuronal damage, and slow down the rate of muscle atrophy.

The initiation of this Phase 2/3 clinical trial is a significant step for CB03-154 in the field of rare diseases, and it brought hopes to provide an important new treatment option for ALS patients.

About Zhimeng 

Founded in 2018, Shanghai Zhimeng Biopharma, Inc. is a biopharmaceutical company dedicated to develop small-molecule drug discovery with focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g. cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and bipolar disorder.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com 

SOURCE Shanghai Zhimeng Biopharma Inc.